Pharma Education Center PEC

pharmaeducationcenter.it

è una Società che ha come missione l'organizzazione di Corsi in house e pubblici di elevato livello culturale nel settore Life Sciences. Nell’organizzazione di PEC, un ruolo chiave per la realizzazione della missione è affidato ai Working Groups; essi costituiscono una comunità scientifica in divenire, che offre agli iscritti opportunità di nuovi contatti, aggiornamento, scambio e condivisione di informazioni e conoscenze tecnico/scientifiche.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

news image

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More

BUSINESS INSIGHTS

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

news image

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More

APRICUS HEALTH PARTNERS WITH MEDICARE ADVANTAGE PLAN DEVOTED HEALTH AND FULL-SERVICE RETAIL PHARMACY LITON RX

Apricus Health | November 04, 2020

news image

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly...

Read More
news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More
news image

BUSINESS INSIGHTS

ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA HAVE SIGNED A COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB)APAMISTAMAB)

Actinium Pharmaceuticals, Inc. | April 13, 2022

Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option. "Immedica has est...

Read More
news image

BUSINESS INSIGHTS

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More
news image

APRICUS HEALTH PARTNERS WITH MEDICARE ADVANTAGE PLAN DEVOTED HEALTH AND FULL-SERVICE RETAIL PHARMACY LITON RX

Apricus Health | November 04, 2020

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly...

Read More